Cagrilintide is an investigational long-acting amylin analogue in development by Novo Nordisk for chronic weight management, and it carries no approval from any major regulator to date. The published trial record splits into two chapters: cagrilintide alone reached placebo-adjusted loss in the high single digits to roughly ten percent of body weight over about six months, while the CagriSema combination with semaglutide reached the mid-teens to low-twenties percent range in phase 3. The evidence points to clinically meaningful loss but reads as still-maturing, regulatory-pending data rather than settled outcomes.
Cagrilintide remains an investigational amylin analogue whose strongest weight-loss evidence comes from the phase 3 CagriSema combination, where mean reductions ran roughly fifteen to twenty-two percent, while the drug carries no regulatory approval to date.
Read on its own, monotherapy cagrilintide established the molecule as a genuinely active weight-loss agent rather than a bit player. Once-weekly dosing produced placebo-adjusted reductions in the high single digits up to about ten percent of baseline body weight at the higher tested doses, measured over roughly twenty-six weeks in adults with overweight or obesity but without type 2 diabetes. Those figures sit below the later combination numbers because the combination stacks a GLP-1 mechanism on top of the amylin analogue.
Once-weekly cagrilintide monotherapy produced placebo-adjusted weight loss in the high single digits to roughly ten percent of baseline body weight over about twenty-six weeks, with a dose-response favoring the higher doses.
The phase 2 work was built to map the efficacy-versus-tolerability curve rather than to prove a single headline number. It stepped participants up through a titration schedule meant to blunt the early gastrointestinal effects of amylin agonism, and it measured percentage change in body weight over roughly six months. Weight loss climbed with dose, and so did nausea and other gastrointestinal complaints, which is the exact tension a dose-finding trial exists to resolve.
The phase 2 dose-finding study identified a higher once-weekly cagrilintide dose as the balance point between weight loss and gastrointestinal tolerability, and validated a titration schedule as the way to reach it.
The phase 3 CagriSema program is the centerpiece of the evidence, pairing cagrilintide with semaglutide across trials that enrolled thousands and ran beyond a year. Mean weight reductions landed in the high teens to roughly the low-twenties percent in adults with obesity but without type 2 diabetes, and lower, generally in the mid-teens, in those who also had diabetes. The headline figure shifts with the estimand reported, since an efficacy estimand that assumes continued adherence yields a larger number than a treatment-policy estimand counting every randomized participant.
| Criterion | Without type 2 diabetes | With type 2 diabetes |
|---|---|---|
| Mean weight reduction | High teens to low-twenties percent | Generally mid-teens percent |
| Relative response | Larger pharmacologic effect | Blunted by diabetes |
| Threshold crossing | Majority passed the 5, 10, and 15 percent marks | Fewer reached the highest thresholds |
In phase 3, the CagriSema combination produced mean weight reductions in the high teens to roughly low-twenties percent in adults with obesity but without type 2 diabetes, and generally mid-teens percent in those who also had type 2 diabetes.
A substantial fraction of participants never reached or stayed on the maximum planned combination dose, which muddies the headline weight-loss figures. When many patients sit below the target dose, the observed average understates what full dosing might deliver, yet it also raises whether the top dose is tolerable enough to be practical outside a trial. The disclosures drew visible reaction from analysts because efficacy came in below the most bullish pre-trial projections.
A substantial share of CagriSema phase 3 participants did not reach or remain on the maximum planned dose, so the headline weight-loss averages understate full-dose potential while leaving real-world tolerability at the top dose unresolved.
Durability is one of the weaker-characterized parts of the record, and what exists has to be read against the broader incretin and amylin class. Inside the trial windows, weight loss accumulated over months toward a plateau rather than reversing, consistent with continued appetite suppression while dosing continues. The unresolved gap is what follows discontinuation, where the class as a whole shows substantial regain once the drug is withdrawn.
Cagrilintide-driven weight loss plateaus during continued dosing but is expected to reverse substantially after discontinuation in line with the broader incretin class, and multi-year durability data beyond the trial windows remains limited.
The sharpest comparison is against semaglutide alone, since CagriSema is semaglutide with cagrilintide added, and the combination's loss exceeds semaglutide monotherapy, which is the core reason for the pairing. Against the marketed dual agonist tirzepatide the picture is murkier: cross-trial figures landed broadly competitive rather than clearly ahead, tempering expectations that the combination would lead the category outright. Most of these rankings rest on cross-trial inference rather than head-to-head data, a weak basis for any firm ordering.
| Criterion | CagriSema (cagrilintide + semaglutide) | Semaglutide alone | Tirzepatide |
|---|---|---|---|
| Reported weight loss | Roughly high-teens to low-twenties percent | Lower than the combination | Broadly competitive with the combination |
| Mechanism | Amylin plus GLP-1 pathways | GLP-1 pathway | GIP plus GLP-1 pathways |
| Comparison basis | Direct vs semaglutide, cross-trial vs tirzepatide | Component of the combination | Cross-trial inference only |
The CagriSema combination produces greater weight loss than semaglutide monotherapy but lands only broadly competitive with tirzepatide across indirect cross-trial comparisons, with no head-to-head randomized data to settle the ranking.
The safety picture is dominated by gastrointestinal effects, expected because both amylin and GLP-1 agonism slow gastric emptying and act on appetite and nausea pathways. Nausea, vomiting, diarrhea, and constipation are the most frequent adverse events, clustering in the dose-escalation window before easing as patients adapt. Most events were mild to moderate, but they still pushed a meaningful minority to discontinue, and combining two agents that both provoke gastrointestinal effects keeps the combination's tolerability burden at least as high as either component alone.
Cagrilintide's adverse-event profile is dominated by mild-to-moderate gastrointestinal effects that cluster during dose escalation and drive a meaningful minority of participants to discontinue, with long-term safety still under regulatory review.
Several gaps should temper any confident reading of the evidence. Most of the strongest data comes from the fixed semaglutide combination, so the amylin analogue's standalone contribution cannot be cleanly isolated, and cagrilintide itself stays investigational with approval pending. Direct head-to-head data, long-term durability evidence, and hard clinical outcome benefits are all still absent.
Cagrilintide remains investigational with approval pending, and its evidence base lacks isolated component data, long-term durability findings, head-to-head randomized comparisons, and demonstrated hard clinical outcome benefits.
Educational use only. This article describes what the published scientific and clinical literature reports about Cagrilintide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
